The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
28th Jun 20192:06 pmRNSAdditional Listing
25th Jun 201912:09 pmRNSResult of AGM
24th Jun 20191:20 pmRNSHolding(s) in Company
21st Jun 20192:36 pmRNSHolding(s) in Company
20th Jun 20191:36 pmRNSHolding(s) in Company
20th Jun 20191:00 pmRNSHolding(s) in Company
19th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20194:37 pmRNSHolding(s) in Company
18th Jun 20191:37 pmRNSHolding(s) in Company
18th Jun 201912:28 pmRNSAdditional Listing
28th May 20197:00 amRNSCollaboration with Genomics England
20th May 20194:46 pmRNSAdditional Listing
14th May 20193:00 pmRNSAdditional Listing
30th Apr 20197:00 amRNSAdditional Listing
26th Apr 20192:35 pmRNSAdditional Listing
25th Apr 20194:55 pmRNSAdditional Listing
25th Apr 20197:00 amRNSSilence Therapeutics Announces Board Changes
18th Apr 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSSilence Therapeutics Publication of Annual Report
16th Apr 201911:00 amRNSSilence Therapeutics Announces Board Change
16th Apr 20197:00 amRNSSilence Therapeutics appoints Head of R&D and CMO
4th Apr 20199:09 amRNSHolding(s) in Company
27th Mar 20197:00 amRNSSilence Therapeutics submits CTA for SLN124
11th Mar 20197:00 amRNS2018 Preliminary Results
7th Mar 20197:00 amRNSSilence to Present at Cowen Healthcare Conference
5th Mar 20197:00 amRNSNotice of Results
4th Mar 20193:35 pmRNSHolding(s) in Company
26th Feb 20195:24 pmRNSHolding(s) in Company
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20197:00 amRNSSLN124 granted Orphan Drug Designation by EMA
9th Jan 20197:00 amRNSDeparture of Chief Financial Officer
19th Dec 20187:00 amRNSSilence Therapeutics advances next RNAi medicine
18th Dec 20184:35 pmRNSPrice Monitoring Extension
10th Dec 20187:00 amRNSSettlement and License Agreement with Alnylam
12th Oct 20186:29 pmRNSErratum: Results of Placing - Withdrawn
12th Oct 20185:12 pmRNSResults of Placing
11th Oct 201810:14 amRNSPTAB Upholds Silence Patent
10th Oct 20187:00 amRNSNew divisional patent and injunction application
5th Oct 20182:16 pmRNSHolding(s) in Company
26th Sep 20187:00 amRNSSilence to Present at Healthcare Conference
21st Sep 20182:19 pmRNSAdditional Listing
11th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
30th Aug 201810:53 amRNSHolding(s) in Company
30th Aug 201810:46 amRNSHolding(s) in Company
24th Aug 20187:00 amRNSNotice of Results
20th Aug 20189:30 amRNSSilence Therapeutics Announces Board Change
7th Aug 20187:00 amRNSLitigation: patisiran EU MA imminent
17th Jul 20183:00 pmRNSDirector/PDMR Shareholding
17th Jul 20181:00 pmRNSAppoints David Horn Solomon as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.